HRP20120975T1 - Terapeutska upotreba anti-cs1 antitijela - Google Patents
Terapeutska upotreba anti-cs1 antitijela Download PDFInfo
- Publication number
- HRP20120975T1 HRP20120975T1 HRP20120975TT HRP20120975T HRP20120975T1 HR P20120975 T1 HRP20120975 T1 HR P20120975T1 HR P20120975T T HRP20120975T T HR P20120975TT HR P20120975 T HRP20120975 T HR P20120975T HR P20120975 T1 HRP20120975 T1 HR P20120975T1
- Authority
- HR
- Croatia
- Prior art keywords
- seq
- antibody
- antigen
- fragment
- binds
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title 1
- 239000012634 fragment Substances 0.000 claims 34
- 102000036639 antigens Human genes 0.000 claims 33
- 108091007433 antigens Proteins 0.000 claims 33
- 239000000427 antigen Substances 0.000 claims 32
- 125000003275 alpha amino acid group Chemical group 0.000 claims 24
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 13
- 230000027455 binding Effects 0.000 claims 13
- 102000004169 proteins and genes Human genes 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 108060003951 Immunoglobulin Proteins 0.000 claims 4
- 102000018358 immunoglobulin Human genes 0.000 claims 4
- 230000028327 secretion Effects 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims 2
- 230000009137 competitive binding Effects 0.000 claims 2
- 229940099039 velcade Drugs 0.000 claims 2
- 101100454807 Caenorhabditis elegans lgg-1 gene Proteins 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55762004P | 2004-03-29 | 2004-03-29 | |
| US55762204P | 2004-03-29 | 2004-03-29 | |
| US55762104P | 2004-03-29 | 2004-03-29 | |
| US10/842,011 US20050025763A1 (en) | 2003-05-08 | 2004-05-07 | Therapeutic use of anti-CS1 antibodies |
| US10/982,357 US7709610B2 (en) | 2003-05-08 | 2004-11-05 | Therapeutic use of anti-CS1 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20120975T1 true HRP20120975T1 (hr) | 2013-01-31 |
Family
ID=44597272
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20120975TT HRP20120975T1 (hr) | 2004-03-29 | 2012-11-28 | Terapeutska upotreba anti-cs1 antitijela |
Country Status (8)
| Country | Link |
|---|---|
| JP (1) | JP4758984B2 (enrdf_load_stackoverflow) |
| CY (1) | CY1115003T1 (enrdf_load_stackoverflow) |
| DK (1) | DK2301576T3 (enrdf_load_stackoverflow) |
| ES (1) | ES2393539T3 (enrdf_load_stackoverflow) |
| HR (1) | HRP20120975T1 (enrdf_load_stackoverflow) |
| IL (1) | IL243687A0 (enrdf_load_stackoverflow) |
| PT (1) | PT2301576E (enrdf_load_stackoverflow) |
| SI (1) | SI2301576T1 (enrdf_load_stackoverflow) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3138282A1 (en) * | 2008-06-02 | 2009-12-10 | Dana-Farber Cancer Institute, Inc. | Xbp1, cd138, and cs1 peptides |
| EP3919069A1 (en) | 2012-11-05 | 2021-12-08 | Dana-Farber Cancer Institute, Inc. | Xbp1, cd138, and cs1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions |
| WO2015166056A1 (en) * | 2014-05-02 | 2015-11-05 | Cellectis | Cs1 specific multi-chain chimeric antigen receptor |
| FI3794042T3 (fi) | 2018-05-18 | 2024-05-31 | Daiichi Sankyo Co Ltd | Anti-muc1-eksatekaani-vasta-aine-lääkekonjugaatti |
| CN112442126B (zh) * | 2019-09-04 | 2022-07-29 | 杭州济元基因科技有限公司 | 一种抗人cs1抗原的单克隆抗体及其car-t细胞 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020123617A1 (en) * | 1999-12-23 | 2002-09-05 | Starling Gary C. | Novel immunoglobulin superfamily members of APEX-1, APEX-2 and APEX-3 and uses thereof |
-
2004
- 2004-11-08 PT PT101807485T patent/PT2301576E/pt unknown
- 2004-11-08 ES ES10180748T patent/ES2393539T3/es not_active Expired - Lifetime
- 2004-11-08 SI SI200431948T patent/SI2301576T1/sl unknown
- 2004-11-08 DK DK10180748.5T patent/DK2301576T3/da active
- 2004-11-08 JP JP2007506135A patent/JP4758984B2/ja not_active Expired - Lifetime
-
2012
- 2012-11-28 HR HRP20120975TT patent/HRP20120975T1/hr unknown
- 2012-11-30 CY CY20121101174T patent/CY1115003T1/el unknown
-
2016
- 2016-01-19 IL IL243687A patent/IL243687A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HK1099699A1 (en) | 2007-08-24 |
| ES2393539T3 (es) | 2012-12-26 |
| IL243687A0 (en) | 2016-04-21 |
| JP4758984B2 (ja) | 2011-08-31 |
| PT2301576E (pt) | 2012-12-20 |
| HK1155670A1 (en) | 2012-05-25 |
| CY1115003T1 (el) | 2016-12-14 |
| JP2007530675A (ja) | 2007-11-01 |
| SI2301576T1 (sl) | 2013-02-28 |
| DK2301576T3 (da) | 2012-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191462T1 (hr) | Antitijela usmjerena protiv her-3 i njihove uporabe | |
| HRP20191999T1 (hr) | Monoklonska protutijela anti-faktora xi i postupci njihove uporabe | |
| HRP20191341T1 (hr) | Protutijela koja vežu ljudski cgrp receptor | |
| RU2015144105A (ru) | Антитела к гепсидину и их применения | |
| HRP20160494T1 (hr) | Antigen-vezujući proteini za proproteinsku konvertazu subtilizin keksin tipa 9 (pcsk9) | |
| US20140212423A1 (en) | Blood-brain barrier penetrating dual specific binding proteins | |
| JP2020536532A5 (enrdf_load_stackoverflow) | ||
| HRP20221260T1 (hr) | Humanizirana i kimerna monoklonska protutijela za cd47 | |
| HRP20201517T1 (hr) | Anti-cd3 protutijela, anti-cd123 protutijela i bispecifična protutijela koja se specifično vežu na cd3 i/ili cd123 | |
| ME02371B (me) | Sastojci i postupci za dijagnstikovanje i tretman raka | |
| HRP20190605T1 (hr) | Protutijela anti-fxi i postupci njihove uporabe | |
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| HRP20110599T1 (hr) | Antitijela protiv toksina clostridium difficile i njihove primjene | |
| RS52889B (sr) | Terapijsko humano anti-il-1r1 monoklonsko antitelo | |
| HRP20120701T1 (hr) | Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1 | |
| RU2009111884A (ru) | Последовательности вариабельных областей моноклональных антител против il-31 и способы использования | |
| RU2010141584A (ru) | Антитело против csf-1r | |
| RU2019121086A (ru) | Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1) | |
| WO2006055809A3 (en) | Antibodies against vascular endothelial growth factor receptor-1 | |
| HRP20210892T1 (hr) | Terapijska uporaba specifičnog liganda u bolestima povezanim s msrv | |
| JP2024024114A5 (enrdf_load_stackoverflow) | ||
| HRP20150934T1 (hr) | Djelovanje na abcb5 u terapiji raka | |
| CN115605511A (zh) | 抗tigit的抗体、其制备方法和应用 | |
| RU2012113554A (ru) | Антитела к рецепту глюкагана и их использование | |
| JP2011526249A5 (enrdf_load_stackoverflow) |